Dr Charlotte Boughton

Research Interests

Our research focuses on the use of new technologies, in particular automated insulin delivery (closed-loop) systems to improve outcomes for people with diabetes.

We undertake randomised controlled clinical trials to evaluate the efficacy and safety of a fully closed-loop approach for people with type 2 diabetes, both as inpatients in the acute hospital setting and as outpatients.

We also investigate the impact of hybrid closed-loop systems in children and adults with type 1 diabetes, and the role of ultra-rapid insulins to enhance performance of automated insulin delivery.

I am currently Chief Investigator for an NIHR EME funded multicentre trial of closed-loop technology for people with cystic fibrosis related diabetes (CL4P-CF).

My Fellowship project investigates the role of automated insulin delivery in achieving remission for adults with recent onset type 2 diabetes.

Group Members

Gosia Wilinska, Research Fellow - mew37 at medschl.cam.ac.uk

Josephine Hayes, Research Study Co-ordinator - jfh31 at cam.ac.uk

Angel Tseung, Project Coordinator - ftt20 at cam.ac.uk

Chloe Royston, PhD Student - cbr29 at cam.ac.uk

Rona Uy, Research Nurse - rgu22 at cam.ac.uk

Rachel Seese, Clinical Research Associate - rs2416 at cam.ac.uk

Rama Lakshman

Funding

Publications

Key publications:

Boughton CK, Hovorka R. The role of automated insulin delivery technology in diabetes. Diabetologia. 2024 May 13.
Boughton CK, Hartnell S, Lakshman R, et al. Fully closed-loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single-center, randomized, crossover study. Diabetes Care. 2023 Nov 1;46(11):1916-1922.
Boughton CK, Hartnell S, Hobday N, et al. Implementation of fully closed-loop insulin delivery for inpatients with diabetes: Real-world outcomes. Diabet Med. 2023 Jun;40(6):e15092.
Daly AB*, Boughton CK*, Nwokolo M, et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023 Jan;29(1):203-208. *joint first author.
Boughton CK, Allen JM, Ware J, et al. Closed-loop therapy and preservation of c-peptide secretion in type 1 diabetes. N Engl J Med. 2022 Sep 8;387(10):882-893.
Boughton CK, Hartnell S, Thabit H et al. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. Lancet Healthy Longev. 2022 Mar;3(3):e135-e142.
Ware J*, Boughton CK*, Allen JM et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health. 2022 Apr;4(4):e245-e255. *joint first author.
Ware J, Allen JM, Boughton CK, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med. 2022 Jan 20;386(3):209-219.
Boughton CK, Tripyla A, Hartnell S, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomised crossover trial. Nat Med. 2021 Aug;27(8):1471-1476.
Boughton CK, Bally L, Martignoni F, et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 May;7(5):368-377.

Research Interests

Group Members

Funding

Publications

Contact Details

partner_logos_updated.png

Study at Cambridge

About the University

Research at Cambridge